T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
|Articles|December 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 12
- Volume 16
- Issue 12
Photography exhibit features breast and ovarian cancer patients and families
Photography exhibit features breast and ovarian cancer patients and families
Advertisement
Articles in this issue
almost 19 years ago
Third-line single-agent cetuximab ups overall survivalalmost 19 years ago
Modern multislice CT propels pancreas imaging forwardalmost 19 years ago
Sorafenib gets ok for liver canceralmost 19 years ago
Celgene to acquire Pharmionalmost 19 years ago
Novacea halts ASCENT-2 trialalmost 19 years ago
RT/temozolomide raises possibility of cure in glioblastomaalmost 19 years ago
Brachytherapy as effective in younger as in older menalmost 19 years ago
MMA not harming patientsalmost 19 years ago
Kinase inhibitor may prevent RT-induced lung injuryalmost 19 years ago
FDA approves lower starting dose for dasatinib for CMLAdvertisement
Related to this article
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
NICE recommended trastuzumab deruxtecan for reimbursement in England for HER2-low metastatic breast cancer, backed by DESTINY-Breast04 data.
Advertisement
Advertisement
Trending on CancerNetwork
1
Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM
2
CELMoD-Based Maintenance Deepens Responses After ASCT in Multiple Myeloma
3
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
4
Subcutaneous Isatuximab Enhances Patient Experience in Multiple Myeloma
5